Stay updated on Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page
- Check3 days agoChange DetectedThe study record shows termination due to slow enrollment and lack of efficacy, with results posted on 2022-10-20.SummaryDifference0.5%

- Check10 days agoNo Change Detected
- Check32 days agoChange DetectedUpgrade notice with updated operating status info and a version bump from v3.1.0 to v3.2.0.SummaryDifference4%

- Check39 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page version has been updated from v3.0.1 to v3.0.2. The non-critical 'Back to Top' element was removed.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as various types of antibodies and proteins. However, many specific medical terms and diseases have been removed, indicating a shift in focus.SummaryDifference5%

Stay in the know with updates to Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.